Cooreman, Michael P. http://orcid.org/0009-0007-3230-7591
Butler, Javed http://orcid.org/0000-0001-7683-4720
Giugliano, Robert P.
Zannad, Faiez http://orcid.org/0000-0001-7456-1570
Dzen, Lucile
Huot-Marchand, Philippe
Baudin, Martine
Beard, Daniel R.
Junien, Jean-Louis
Broqua, Pierre
Abdelmalek, Manal F.
Francque, Sven M. http://orcid.org/0000-0002-7527-4714
Funding for this research was provided by:
The clinical study NATIVE was funder by Inventiva.
Article History
Received: 12 October 2023
Accepted: 16 April 2024
First Online: 10 May 2024
Competing interests
: M.P.C., L.D., P.H.M., M.B. and P.B. are employees of Inventiva. J.L.J. is a consultant for Inventiva. D.R.B. has received honoraria from Inventiva via Translational Medicine Academy. J.B. has served as a consultant for Abbott, American Regent, Amgen, Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, Cardiorem, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Regeneron, Renibus, Roche, Salamandra, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, and Zoll. RPG received research support or honoraria form Amgen, Anthos Therapeutics, Daiichi Sankyo, Ionis, Dr. Reddy’s Laboratories, Medical Education Resources, Menarini, SAJA Pharmaceuticals, Servier, SUMMEET, and consults for Artivion, Beckman Coulter, Daiichi Sankyo, Gilead, Inari, Inventiva, PhaseBio Pharmaceuticals, Samsung and Aventis. FZ reports personal fees from 89Bio, Abbott, Acceleron, Applied Therapeutics, Bayer, Betagenon, Boehringer, BMS, CVRx, Cambrian, Cardior, Cereno pharmaceutical, Cellprothera, CEVA, Inventiva, KBP, Merck, NovoNordisk, Owkin, Otsuka, Roche Diagnostics, Northsea, USa2, having stock options at G3Pharmaceutical and equities at Cereno, Cardiorenal, Eshmoun Clinical research and being the founder of Cardiovascular Clinical Trialists. MFA received grants from Boehringer-Ingelheim, Gilead, Hanmi, Inventiva, Madrigal, Novo Nordisk; honoraria from Clinical Care Options, Fishawack, Medscape, Terra Firma, CLDF; royalties from Up-to-Date; consults for 89Bio, BMS, Hanmi, Inventiva, Intercept, Madrigal, Merck, Novo Nordisk. SMF received grants from Astellas, Falk Pharma, Genfit, Gilead Sciences, GlympsBio, Janssens Pharmaceutica, Inventiva, Merck Sharp & Dome, Pfizer, Roche; honoraria from Abbvie, Allergan, Bayer, Eisai, Genfit, Gilead Sciences, Janssens Cilag, Intercept, Inventiva, Merck Sharp & Dome, Novo Nordisk, Promethera, Siemens; serves as consultant for Abbvie, Actelion, Aelin Therapeutics, AgomAb, Aligos Therapeutics, Allergan, Alnylam, Astellas, Astra Zeneca, Bayer, Boehringer Ingelheim, Bristoll-Meyers Squibb, CSL Behring, Coherus, Echosens, Dr. Falk Pharma, Eisai, Enyo, Galapagos, Galmed, Genetech, Genfit, Genflow Biosciences, Gilead Sciences, Intercept, Inventiva, Janssens Pharmaceutica, PRO.MED.CS Praha, Julius Clinical, Madrigal, Medimmune, Merck Sharp & Dome, Mursla Bio, NGM Bio, Novartis, Novo Nordisk, Promethera, Roche, Siemens Healthineers.